Fig 1.
LDL-C, Low-density lipoprotein cholesterol; LLT, Lipid-lowering therapy; DLCN, Dutch Lipid Clinic Network; FH, Familial hypercholesterolemia. aAn unlikely FH refers to a DLCN score of 0 to 2 points. bA possible FH refers to a DLCN score of 3 to 5 points. cA probable FH refers to a DLCN score of 6 to 8 points. dA definite FH refers to a DLCN score of above 8 points.
Table 1.
Demographic characteristics and comorbidities of patients with probable or definite FH at baseline.
Fig 2.
Lipid panel of study subjects at baseline.
Min, Minimum; Max, Maximum; Q, Quartile. aNumber of days to index-date: For all patients: Min: 0; Q1: 5; Q2: 43; Q3: 287; Max: 726; For patients with Definite FH: Min: 0; Q1: 8.5; Q2: 51.5; Q3: 333.5; Max: 687; For patients with Probable FH: Min: 0; Q1: 5; Q2: 25; Q3: 229; Max: 726. bNumber of days to index-date: For all patients: Min: 0; Q1: 5.5; Q2: 43; Q3: 265.5; Max: 726; For patients with Definite FH: Min: 0; Q1: 15; Q2: 54; Q3: 347; Max: 687; For patients with Probable FH: Min: 0; Q1: 5; Q2: 22; Q3: 199; Max: 726. cNumber of days to index-date: For all patients: Min: 0; Q1: 6; Q2: 47.5; Q3: 310.5; Max: 726; For patients with Definite FH: Min: 0; Q1: 15; Q2: 84; Q3: 347; Max: 709; For patients with Probable FH: Min: 0; Q1: 5; Q2: 25; Q3: 297; Max: 726. dThe index date is the date of the first entry of the DLCN score of the patient by the consented physician into the database.
Table 2.
Pharmacological management and clinical outcomes of patients with probable or definite FH, at baseline and at 6-month of follow-up.
Fig 3.
LLT change status of patients with definite or probable FH at 6-month of follow-up.
Discontinued defined as any LLT prescription at index date but no LLT prescription at 6-month of follow-up. Switching defined as different LLT/combination of LLT prescribed during follow-up than the LLT prescribed at index date. Increase defined as one or more new LLT started during follow-up with index drugs also still continued. Decrease defined as one or more LLT at index date no longer taken at follow-up, but one or more LLT at index date still continued. No change defined as no change in LLT drugs prescribed between index date and follow-up.